Skip to main content

Boston Scientific Value Stock - Dividend - Research Selection

Boston Scientific

ISIN: US1011371077, WKN: 884113

Market price date: 06.04.2020
Market price: 32,88 USD




Boston Scientific Fundamental data and company key figures of the share

Annual reports in USD
Key figures 27-02-2020
Cash flow
Net operating cash flow 1.836.000.000
Capital Expenditures -461.000.000
Free cash flow 1.375.000.064
Balance sheet
Total Equity 13.877.000.000
Liabilities & Shareholders equity 30.565.000.000
Income statement
Net income 4.700.000.000
Eps (diluted) 3,330
Diluted shares outstanding 1.411.410.000
Net sales/revenue 10.735.000.000

Fundamental ratios calculated on: 06-04-2020

Ratios
Key figures 06-04-2020
Cash flow
P/C 25,28
   
P/FC 33,75
Balance sheet
ROI15,38
ROE45,40
Income statement
P/E9,87
Div. Yield0,00%
P/B3,34
P/S4,32


Do you want to do make a detailed fundamental analysis of this stock?

Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
SymbolBSX
Market Capitalization43.993.649.152,00 USD
CountryUnited States
IndicesS&P 500
SectorsHealth service
Raw Data SourceUS GAAP in Millionen USD
Stock Split2003-11-06,2.0000/1.0000; 1998-12-01,2.0000/1.0000
Internetwww.bostonscientific.com


Description of the company

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: Cardiovascular, Rhythm Management, and MedSurg. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems. It also provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy systems, wires, and stents to treat venous diseases; and peripheral embolization devices, microcatheters, and drainage catheters to treat various cancers. In addition, the company offers cardiac rhythm management devices, such as implantable cardioverter defibrillator systems to treat abnormalities; remote patient management system; implantable cardiac resynchronization therapy pacemaker systems; and medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising ablation catheters, intracardiac ultrasound catheters, diagnostic catheters, delivery sheaths, mapping system, and other accessories. Further, it provides products to diagnose and treat diseases of the gastrointestinal and pulmonary conditions; devices to diagnose, treat, and palliate pulmonary diseases within the airway and lungs; and products to treat various urological and pelvic conditions; deep brain stimulation systems for the treatment of parkinson\'s disease, tremor, and intractable primary and secondary dystonia; and spinal cord stimulator systems for the management of chronic pain. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov, www.bostonscientific.com